The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer’s Disease
- 14 December 2015
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 49 (3) , 681-693
Abstract
The altered metabolism of iron impacts the brain function in multiple deleterious ways during normal aging as well as in Alzheimer’s disease. We have shown in this study that chelatable iron accumulates in the aged rat brain along with overexpression of transferrin receptor 1 (TfR1) and ferritin, accompanied by significant alterations in amyloid-β (Aβ) peptide homeostasis in the aging brain, such as an increased production of the amyloid-β protein precursor, a decreased level of neprilysin, and increased accumulation of Aβ42. When aged rats are given daily the iron chelator, deferasirox, over a period of more than 4 months starting from the 18th month, the age-related accumulation of iron and overexpression of TfR1 and ferritin in the brain are significantly prevented. More interestingly, the chelator treatment also considerably reverses the altered Aβ peptide metabolism in the aging brain implying a significant role of iron in the latter phenomenon. Further, other results indicate that iron accumulation results in oxidative stress and the activation of NF-κB in the aged rat brain, which are also reversed by the deferasirox treatment. The analysis of the results together suggests that iron accumulation and oxidative stress interact at multiple levels that include transcriptional and post-transcriptional mechanisms to bring about changes in the expression levels of TfR1 and ferritin and also alterations in Aβ peptide metabolism in the aging rat brain. The efficacy of deferasirox in preventing age-related changes in iron and Aβ peptide metabolism in the aging brain, as shown here, has obvious therapeutic implications for Alzheimer’s disease.Keywords
This publication has 77 references indexed in Scilit:
- Regulation of brain iron and copper homeostasis by brain barrier systems: Implication in neurodegenerative diseasesPharmacology & Therapeutics, 2012
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approachActa Neuropathologica, 2011
- Regulation of cellular iron metabolismBiochemical Journal, 2011
- Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's diseaseBiochemical Society Transactions, 2008
- Role of HIF-1 and NF-κB Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory SignalsJournal of Biological Chemistry, 2008
- Intracellular Iron Transport and Storage: From Molecular Mechanisms to Health ImplicationsAntioxidants & Redox Signaling, 2008
- Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's diseaseTrends in Molecular Medicine, 2008
- Copper binding to the Alzheimer’s disease amyloid precursor proteinEuropean Biophysics Journal, 2007
- Iron, brain ageing and neurodegenerative disordersNature Reviews Neuroscience, 2004
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001